Kawasaki Disease Clinical Trial
Official title:
Prevalence and Early Markers of Atherosclerosis in Adults With a History of Kawasaki Disease
Kawasaki disease (KD) is an acute systemic vasculitic syndrome with coronary tropism.
It has been reported worldwide, but it is ten times more common in Asian population. The
annual incidence in children under 5 years in Europe is estimated at 8 to 100000. It is the
second vasculitis of the child by its frequency after rheumatoid purpura. It occurs in 80% of
cases between 1 and 5 years, with a maximal incidence around the age of 12 months.
It may results in acquired heart disease in children in developed countries, and may be the
cause of premature coronary artery disease in adulthood.
A polymorphism was recently associated with the occurrence of disease in a Japanese and U.S
population. (C allele of SNP itpkc_3, with a risk multiplied by 2). However, data are
conflicting on this issue and the prevalence of this allel is unknown in North America and
Europe populations.
The clinical picture of KD associate a persistent fever and an antipyretics resistance with
mucocutaneous signs and bulky cervical lymphadenopathy usually unilateral. Diagnosis is
confirmed by the presence of five clinical signs (major criteria). The presence of
inconsistent coronary lesions in cardiac ultrasound can confirm the diagnosis.
KD can resolve spontaneously with no treatment. The severity of the disease is primarily
related to complications of coronary aneurysms in acute or chronic stages.
Several arguments support the fact that adult patients have diffuse vascular lesions
different from aneurysmal lesions initially described in childhood.
Despite abundance of publications on KD, there is no prospective or retrospective study which
explored anomalies resulting from KD in adult subjects.
Therefore, this project will describe the patient's vascular evolution, the prevalence of
atherosclerotic lesions and to determine the biological and functional abnormalities, markers
of accelerated atherosclerosis.
Hypothesis : A history of Kawasaki disease represents a cardiovascular risk factor in
adulthood.
The main objective is to evaluate the prevalence of atherosclerotic lesions, their extent and
their severity in adults with a history of KD in childhood compared to a control population.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05911386 -
Multiparametric Echocardiography and Cardiac Biomarkers in Pediatric Inflammatory Heart Diseases
|
||
| Recruiting |
NCT02951234 -
A Multi-center, Randomized to Compare the Efficacy of IVIG Alone and IVIG Plus High-dose Aspirin in Kawasaki Disease
|
N/A | |
| Active, not recruiting |
NCT02853266 -
Measurement of Antibodies in Adults With a History of Kawasaki Disease
|
N/A | |
| Active, not recruiting |
NCT04747847 -
Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease
|
Early Phase 1 | |
| Withdrawn |
NCT04535518 -
Efficacy of Immunoglobulin Plus Infliximab for the Early Regression of Coronary Artery Lesion in Kawasaki Disease
|
Phase 3 | |
| Recruiting |
NCT01917721 -
Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease
|
Phase 2 | |
| Recruiting |
NCT04656184 -
A Trial Comparing the Efficacy and Safety of Anakinra Versus Intravenous Immunoglobulin (IVIG) Retreatment, in Patients With Kawasaki Disease Who Failed to Respond to Initial Standard IVIG Treatment
|
Phase 3 | |
| Recruiting |
NCT03200561 -
A Trial to Evaluate the Efficacy of Immunoglobulin Plus Steroid for Prevention of Coronary Artery Abnormalities in Taiwanese Refractory Kawasaki Disease (RAST Study)
|
Phase 3 | |
| Completed |
NCT02179853 -
Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT02980263 -
Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease
|
Phase 2 | |
| Enrolling by invitation |
NCT02359643 -
Multi-center Prospective Randomized Control Trail of High Dose Aspirin in Acute Stage of Kawasaki Disease
|
N/A | |
| Recruiting |
NCT04278404 -
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
|
||
| Completed |
NCT00760435 -
Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease
|
Phase 3 | |
| Completed |
NCT00841789 -
A Randomized, Double Blind, Placebo Controlled Study of Etanercept in Children With Kawasaki Disease
|
Phase 2 | |
| Not yet recruiting |
NCT05643651 -
Rivaroxaban for Children With Giant Coronary Artery Aneurysms After Kawasaki Disease
|
Phase 4 | |
| Recruiting |
NCT02114099 -
Trial of Atorvastatin on the Persistent Coronary Aneurysm in Children With Kawasaki Disease
|
Phase 2 | |
| Not yet recruiting |
NCT05091229 -
A Blood Test to Diagnose Kawasaki Disease
|
||
| Completed |
NCT01431105 -
Pharmacokinetics (PK)/Safety Study of Atorvastatin in Children With Kawasaki Disease and Coronary Artery Abnormalities
|
Phase 1/Phase 2 | |
| Recruiting |
NCT01793168 -
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
|
||
| Recruiting |
NCT06305611 -
European and North Indian Cohort of KaWasaki dIsease
|